Belzutifan
- Generic Name
- Belzutifan
- Brand Names
- Welireg, 维利瑞
- Drug Type
- Small Molecule
- Chemical Formula
- C17H12F3NO4S
- CAS Number
- 1672668-24-4
- Unique Ingredient Identifier
- 7K28NB895L
- Background
Belzutifan is an inhibitor of hypoxia-inducible factor 2α (HIF-2α) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers. The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. Initially considered to be undruggable, a binding pocket was eve...
- Indication
Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), who do not require immediate surgery.
- Associated Conditions
- Hemangioblastoma, Pancreatic Neuroendocrine Cancer, Renal Cell Carcinoma (RCC)
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.